A Study to Evaluate the Pharmacokinetics and Safety of IN-M00007 and IN-R00007 in Healthy Adult Volunteers

NCT ID: NCT07311811

Last Updated: 2025-12-31

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2026-04-30

Brief Summary

This study aims to evaluate the Pharmacokinetic (PK) characteristics and safety after a single oral dose administration of IN-M00007 and IN-R00007 in healthy adult volunteers

Detailed Description

An open label, randomized, single oral dose, crossover study

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sequence A

R → T R: IN-R00007, T: IN-M00007

Group Type: EXPERIMENTAL

IN-R00007

Intervention Type: DRUG

Single dose

IN-M00007

Intervention Type: DRUG

Single dose

Sequence B

T → R R: IN-R00007, T: IN-M00007

Group Type: EXPERIMENTAL

IN-R00007

Intervention Type: DRUG

Single dose

IN-M00007

Intervention Type: DRUG

Single dose

Interventions

IN-R00007

Single dose

Intervention Type: DRUG

IN-M00007

Single dose

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy adult volunteers aged ≥ 19 and < 60 years at screening

2. Body mass index(BMI) in the range of 18.0 and 30.0 kg/㎡

• Body weight ≥ 50kg for male
• Body weight ≥ 45kg for female

3. Subjects who do not have significant congenital or chronic diseases and without pathological symptoms or findings based on medical examinations(if necessary, EEG, ECG, chest X-ray, gastroscopy or gastrointestinal radiographic tests)

4. Determined by the investigator to be eligible for study participation based on the results of screening tests (e.g. hematology test, blood chemistry test, serology test, urinalysis, pregnancy diagnostic tests) conducted according to the IP characteristics

5. Subjects who voluntarily signed the consent form after receiving detailed explanation and understanding about purpose, details, characteristics of the IP and anticipated adverse events of the study

6. Subjects who agree to use highly effective methods of contraception(excluding hormonal methods) to preclude the possibility of pregnancy of themselves or their spouse/partner from the first IP administration until 14 days after the last administration, and who agrees not to donate sperm or ovum during this period

• Highly effective contraceptive methods: intrauterine device(IUD), bilateral tubal ligation, a partner who has undergone vasectomy, or sexual abstinence However, periodic abstinence(calendar method, symptothermal method, post-ovulation method), withdrawal intercourse(coitus interruptus), spermicide methods, lactational amenorrhea method, and simultaneous use of female and male condoms are not considered contraceptive methods

Exclusion Criteria

1. Subjects who have taken drugs which can induce(e.g, Barbiturates) or inhibit drug metabolism enzyme within 30 days prior to the start of the study(first IP administration day) or have taken medications that may affect this study within 10 days prior to the start of the study(first IP administration day)

2. Subjects who have participated in any other clinical study or bioequivalence study and administered IP within 6 months

3. Subjects who have donated whole blood within 8 weeks prior to the start of the study(first IP administration day) or have donated component blood within 2 weeks prior to the start of the study(first IP administration day)

4. Subjects with a history of gastrointestinal resection that may affect drug absorption(excluding appendectomy and hernia operation)

5. Subjects meeting following conditions within 1 month prior to the start of the study(first IP administration day)

• Alcohol consumption > 21 glasses per week for male
• Alcohol consumption > 14 glasses per week for female

6. Subjects with the following diseases

• Subjects with hypersensitivity to the ingredient or components of this drug
• Subjects with active liver disease or those with persistently elevated serum aminotransferase levels of unknown cause
• Subjects with muscular disorders
• Subjects receiving concomitant administration with cyclosporine
• Subjects with severe renal impairment or kidney dysfunction
• Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

7. Subjects with a clinically significant history of mental illness

8. Pregnant or breastfeeding women if female

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 59 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

HK inno.N Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hyeonggeon Kim

Role: PRINCIPAL_INVESTIGATOR

H Plus Yangji Hospital

Locations

H PLUS Yangji Hospital, Clinical Trial Center

Seoul, , South Korea

Countries

South Korea

Central Contacts

Heeju Ahn

Role: CONTACT

Phone: +82 31-5176-4662

Email: heeju.ahn21@inno-n.com

Yugyeong Park

Role: CONTACT

Phone: +82 31-5176-4661

Email: yugyeong.park@inno-n.com

Other Identifiers

IN_RVZ_104

Identifier Type: -

Identifier Source: org_study_id